Recombinant human rhgm csf

Manufactured by R&D Systems

Sourced in United States

Recombinant human rhGM-CSF is a laboratory product produced by R&D Systems. It is a hematopoietic growth factor that stimulates the production and differentiation of granulocytes and macrophages.

Automatically generated - may contain errors

Lab products found in correlation

Rhil 4, by R&D Systems (3 mentions) Gentamicin, by R&D Systems (2 mentions) 1640 medium, by Thermo Fisher Scientific (2 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (2 mentions) Streptomycin, by Thermo Fisher Scientific (2 mentions) Streptomycin, by R&D Systems (1 mentions) Fetal calf serum (fcs), by Thermo Fisher Scientific (1 mentions) Anti cd14 microbeads, by Miltenyi Biotec (1 mentions) Ly294002, by Cell Signaling Technology (1 mentions) Bi d1870, by Selleck Chemicals (1 mentions) Pf 4708671, by Selleck Chemicals (1 mentions) Rhil 5, by BD (1 mentions) Control mouse igg1, by Agilent Technologies (1 mentions) Control goat igg, by R&D Systems (1 mentions) Human serum igg, by Merck Group (1 mentions) Rhil 6, by R&D Systems (1 mentions) Dmem media, by Thermo Fisher Scientific (1 mentions) Human ab serum, by Gemini Bio (1 mentions) Polymixin b, by Merck Group (1 mentions) Rhgm csf, by R&D Systems (1 mentions)

Close spelling variants of this product

Recombinant human GM-CSF (rhGM-CSF; RhGM-CSF

5 protocols using recombinant human rhgm csf

Monocyte-Derived Dendritic Cell Generation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fresh peripheral blood mononuclear cells (PBMCs) obtained from 40 mL of each individual were used for monocytes purification by means of anti-CD14 microbeads following the manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). To generate DCs, monocytes (CD14+ cells) were incubated in complete medium (CM) containing Roswell Park Memorial Institute 1640 medium (Life Technologies, Invitrogen, Carlsbad, CA, USA) supplemented with 10% Fetal Calf Serum (FCS; Life Technologies, Carlsbad, CA, USA), streptomycin (100 µg·mL⁻¹), gentamicin (1.25 U·mL⁻¹) as well as recombinant human rhGM-CSF (200 ng·mL⁻¹) and rhIL-4 (100 ng·mL⁻¹) (both from R & D Systems Inc., Minneapolis, MN, USA) for 5 days at 37 °C and 5% CO₂. The resulting DCs were then recovered and used in the experiments.
The study was conducted according to the declaration of Helsinki and all patients and controls participating in the study gave their informed consent and protocols were approved by institutional ethical committees (Ethical Committee of Malaga).

Mesa-Antunez P., Collado D., Vida Y., Najera F., Fernandez T., Torres M.J, & Perez-Inestrosa E. (2016). Fluorescent BAPAD Dendrimeric Antigens Are Efficiently Internalized by Human Dendritic Cells. Polymers, 8(4), 111.

+ Open protocol

+ Expand

Eosinophil Degranulation Inhibition Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human (Rh) GM-CSF was purchased from R&D Systems Inc (Minneapolis, MN, USA), while rhIL-3 and rhIL-5 were purchased from BD Biosciences (San Jose, CA, USA). Human serum IgG was from Sigma-Aldrich (St. Louis, MO), LY294002 from Cell Signaling (Danvers, MA), and BI-D1870 and PF-4708671 from Selleckchem (Houston, TX). For the neutralization of IL-3-activated eosinophil degranulation on aggregated IgG, polyclonal goat anti-FCGRIIB/C and anti-FCGRIIA antibodies and control goat IgG were from R&D systems (Minneapolis, MN). Neutralizing anti-αM/CD11b (mouse, clone 2LPM19c) was from Biomeda (Foster City, CA), anti-ß1 integrin (rat, clone mAb13) was from Sigma, and the anti-ß7 (rat, clone Fib504) was from BD Biosciences (San Jose, CA). The control mouse IgG₁ and the control rat IgG2a were from Dako (Carpinteria, CA) and Santa Cruz Biotechnologies (Dallas, Texas), respectively. All the neutralizing anti-integrin antibodies have been described previously [33 (link)].

Esnault S., Johansson M.W., Kelly E.A., Koenderman L., Mosher D.F, & Jarjour N.N. (2017). IL-3 Up-regulates and Activates Human Eosinophil CD32 and αMß2 Integrin Causing Degranulation. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 47(4), 488-498.

+ Open protocol

+ Expand

Monocyte-Derived Dendritic Cell Generation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fresh peripheral
blood mononuclear
cells, obtained by a ficoll gradient, from 40 mL of blood per individual,
were used for monocyte purification by means of anti-CD14 microbeads
following the manufacturer’s protocol (Miltenyi Biotec, Bergisch
Gladbach, Germany). The CD14– cell fraction was placed in 10%
DMSO and frozen for a later lymphocyte proliferation test. To generate
DCs, monocytes (CD14+ cells) were incubated in complete medium containing
Roswell Park Memorial Institute 1640 medium (Thermo Fisher Scientific,
Carlslab, CA) supplemented with 10% fetal bovine serum (Thermo Fisher
Scientific), streptomycin (100 μg/mL), and gentamicin (1.25
U/mL), as well as recombinant human rhGM-CSF (200 ng/mL) and rhIL-4
(100 ng/mL) (both from R&D Systems Inc., Mineapolis, MN) for 5
days at 37 °C and 5% CO₂.

Losada Méndez J., Palomares F., Gómez F., Ramírez-López P., Ramos-Soriano J., Torres M.J., Mayorga C, & Rojo J. (2021). Immunomodulatory Response of Toll-like Receptor Ligand–Peptide Conjugates in Food Allergy. ACS Chemical Biology, 16(11), 2651-2664.

+ Open protocol

+ Expand

Culturing Murine Myeloid-Derived Suppressor Cells

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Femoral BM cells (20 × 10⁶) were cultured in T75cm² flasks for 7 days (d) in DMEM media (ThermoFisher Scientific, Waltham, MA) supplemented with 7% v/v human AB serum (Gemini Bio-Products, Sacrameto, CA), recombinant human (rh) GM-CSF (80 ng/ml) and rhIL-6 (15 ng/ml) (RD Systems, Minneapolis, MN). Fresh cytokines were added on d 3 and 5 of culture. mMDSC flow-sorted from the peripheral blood of G- and GM-CSF-treated rhesus macaques as described [16 (link)] were used in functional comparison experiments.

Zahorchak A.F., Perez-Gutierrez A., Ezzelarab M.B, & Thomson A.W. (2018). Monocytic myeloid-derived suppressor cells generated from rhesus macaque bone marrow enrich for regulatory T cells. Cellular immunology, 329, 50-55.

+ Open protocol

+ Expand

Generating Canine and Human MoDCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human and canine MoDCs were generated as previously described [9] . Monocytes were isolated from peripheral blood mononuclear cells (PBMCs) using an anti-human CD14 monoclonal antibody (clone TÜK4) conjugated to magnetic beads (MACS ® ; Miltenyi Biotec, Bergisch Gladbach, Germany), previously shown to cross-react with canine CD14 [11] . The CD14 + monocytes were seeded at 10 6 cells/ mL in RPMI-1640 (Life Technologies, Gaithersburg, MD, USA), containing 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine (Gibco Invitrogen Corp., Grand Island, NY, USA) and 100 U/mL polymixin B (Sigma-Aldrich, St. Louis, MO, USA).
Canine cell cultures were supplemented with 40 ng/mL recombinant human (rh) GM-CSF and 30 ng/mL recombinant canine (rc) IL-4 (R&D Systems Inc., Minneapolis, MN, USA), while human cells cultures were supplemented with 20 ng/mL rhGM-CSF and rhIL-4 (R&D Systems Inc.) every 2 days. Differentiated MoDCs were then primed with live B. canis (MOI=200), 1 µg/mL B. canis purified LPS or 1 µg/mL LPS from Escherichia coli strain 0128:B12 (Sigma-Aldrich, St. Louis, MO, USA) for 24 hours. Non-stimulated MoDCs were used as negative control. For each individual, experiments were performed separately.

Pujol M., Borie C., Montoya M., Ferreira A, & Vernal R. (2019). Brucella canis induces canine CD4⁺ T cells multi-cytokine Th1/Th17 production via dendritic cell activation. Comparative immunology, microbiology and infectious diseases, 62.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!